Konstantinos Syrigos to Biomarkers, Tumor
This is a "connection" page, showing publications Konstantinos Syrigos has written about Biomarkers, Tumor.
Connection Strength
0.695
-
Circulating tumor cells count as a predictor of survival in lung cancer. Crit Rev Oncol Hematol. 2018 May; 125:60-68.
Score: 0.372
-
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. J Thorac Oncol. 2018 12; 13(12):1884-1896.
Score: 0.097
-
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017 07; 109:101-108.
Score: 0.088
-
High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res. 2009 Jun 15; 15(12):4157-64.
Score: 0.051
-
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res. 2019 08 01; 25(15):4663-4673.
Score: 0.025
-
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 04 01; 24(7):1562-1573.
Score: 0.023
-
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clin Cancer Res. 2017 Sep 01; 23(17):5202-5209.
Score: 0.022
-
Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014 Jan; 94(1):107-16.
Score: 0.017